Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of [177Lu]Lu-EVS459 in ovarian and lung cancers
NL-OMON59232Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EVS459 in ovarian cancer and non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Novartis. Primary endpoint: Primary endpoint(s). Started Dec 2024; status: completed.
02
Drugs
EVS459
03
Conditions
ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59232.